Vitrase (Hyaluronidase,Ovine) Patent Expiration, LOE Window & CMS Spending

Vitrase (Hyaluronidase,Ovine) by Bausch Health: Biologic BLA (Purple Book Regime), 0 AB generics, $40K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayB021640 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$40K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.